A real-world study of apatinib mesylate in the treatment of locally advanced Colorectal cancer during the perioperative period

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054122

Enrollment

Unknown

Registered

2021-12-09

Start date

2021-12-30

Completion date

Unknown

Last updated

2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Apatinib Mesylate Tablets group:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, gender is not limited; 2. Locally advanced colorectal adenocarcinoma confirmed by histology or cytology; 3. Stage T3 assessed by computed tomography/magnetic resonance imaging; 4. The patients voluntarily joined the study and signed the informed consent; 5. Physicians believe that they can benefit, voluntarily accept apatinib mesylate treatment and participate in this study.

Exclusion criteria

Exclusion criteria: 1. Those who have proved allergic to apatinib mesylate tablets and/or its excipients; 2. Pregnant or lactating women; 3. Patients with contraindications to apatinib; 4. The researcher thinks it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
R0 resection rate;Tumor regression grade;	—

Secondary

Measure	Time frame
Progression-free survival;Total survival time;Disease remission rate;Disease control rate;Safety;Quality of Life;	—

Countries

China

Contacts

Public ContactZhang Aimin

Affiliated Hospital of Hebei University

hdfyzam@126.com+86 13733398886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026